Nutex Health Inc. NUTX
220.11
15.52
7.59%
as of 25 Sep
- Market cap
- $1.4B
- P/E
- 8.4×
Follow NUTX
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
6.56 | 7.03 | 17.38 | 5.22 |
+8 more quarters Free account |
P/S ratio |
1.39 | 0.75 | 1.20 | 0.71 | |
P/FCF ratio |
4.28 | 2.47 | 4.26 | 3.93 | |
P/Operating CF |
34.33 | 8.80 | 14.88 | 6.96 | |
P/B ratio |
2.31 | 1.50 | 2.47 | 1.58 | |
Price to Tangible BV |
2.48 | 1.63 | 2.70 | 1.72 | |
EV/Sales |
1.50 | 0.87 | 1.33 | 0.86 | |
EV/EBITDA |
3.29 | 2.57 | 3.92 | 2.23 | |
EV/Operating CF |
4.53 | 2.80 | 4.68 | 4.75 | |
EV/FCF |
4.62 | 2.84 | 4.72 | 4.80 | |
Quick Ratio |
4.81 | 3.02 | 3.24 | 3.09 | |
Current Ratio |
5.00 | 3.14 | 3.41 | 3.20 | |
Net Debt/EBITDA |
0.73 | 1.14 | 3.13 | 1.13 | |
Debt/Assets |
31.11% | 32.37% | 32.53% | 33.07% | |
Debt/Equity |
0.59 | 0.70 | 0.71 | 0.73 | |
Asset Turnover |
0.94 | 1.02 | 1.11 | 1.40 | |
Operating CF/Net income |
0.52 | 1.61 | 5.95 | 1.80 | |
Capex/Depreciation |
(0.48) | (0.22) | (0.27) | (0.06) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
9.28% | 4.83% | 10.03% | 9.15% | |
Intangible Assets out of Total Assets |
0.04 | 0.04 | 0.04 | 0.04 | |
Share Based Compensation of Revenue |
1.37% | (1.81%) | (1.72%) | 4.94% | |
Graham Net Nets |
0.11 | 0.10 | 0.04 | 0.10 | |
Graham Number |
208.03 | 138.70 | 119.09 | 170.65 | |
Earnings Yield |
15.24% | 14.23% | 5.75% | 19.16% | |
Free Cash Flow Yield |
23.35% | 40.50% | 23.45% | 25.46% | |
Revenue per Share |
30.67 | 30.97 | 23.84 | 39.96 | |
Operating CF per Share |
4.98 | 10.80 | 11.07 | 14.85 | |
Capex per Share |
(0.37) | (0.17) | (0.22) | (0.05) | |
Free Cash Flow per Share |
4.61 | 10.63 | 10.84 | 14.81 | |
Cash per Share |
30.14 | 30.14 | 29.22 | 24.78 | |
Shareholders Equity per Share |
73.83 | 63.24 | 66.56 | 65.37 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
73.83 | 63.24 | 66.56 | 65.37 | |
Free Cash Flow |
31.66 | 74.32 | 68.98 | 99.21 | |
Working Capital |
468.43 | 395.21 | 380.90 | 407.20 | |
Capital Expenditures |
(2.54) | (1.20) | (1.41) | (0.30) | |
Net Current Asset Value |
128.33 | 64.38 | 43.72 | 66.17 | |
EV/EBIT |
3.48 | 2.76 | 4.21 | 2.35 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.00 | |
Net Profit Margin |
31.24% | 21.62% | 7.80% | 20.70% | |
Price to Operating Income |
3.22 | 2.40 | 3.80 | 1.93 | |
| Other line items | |||||
Average Receivables |
355.83 | 322.62 | 280.73 | 236.60 | |
Average Payables |
20.01 | 36.17 | 29.69 | 33.11 | |
Average Inventory |
3.24 | 3.90 | 2.86 | 2.71 | |
Average Assets |
902.83 | 859.62 | 786.92 | 701.50 | |
Average Common Equity |
422.09 | 348.66 | 305.99 | 258.91 |
Columns are period end dates